Zurich Corporate Risk has launched two new services, Precision CancerCare™ and Second Medical Opinion (SMO), as part of its group risk employee benefits for new and reviewing customers.
The cancer care service will give workers access to genetic testing using tumour profiling technology and expert medical panels.
The provider said that cancer is the leading cause of claims for the group, so the service has been designed in partnership with specialist health service Further to offer employer customers, and their employees, access to the best cancer support.
Each case is different, so by understanding the genetic make-up of the cancer, the service provides a customised treatment plan specific to the molecular drivers of the tumour. The provider said that this can potentially improve a patient’s outcomes, reduce negative side effects of unnecessary treatments and help improve overall quality of life. Employees will also be given an expert clinical report with personalised guidance regarding cancer treatment options and advice.
This service is accessible for all advanced and complex cancers, which is where the provider expects to see the biggest impact.
In addition, if the tests identify a hereditary mutation that could affect children, employees will be offered further testing and counselling to help them make decisions about future health.
Second Medical Opinion
Employer customers will have access to a new SMO service, also provided by Further, to support people that are unsure about a diagnosis or treatment plans.
This offers an independent evaluation of a diagnosis, treatment plan, or medical condition from a qualified medical professional other than a patient’s primary doctor.
The service is available once per unique diagnosis, and support is offered for spouses or partners, and dependent children up to age 22.
Cindy Warden, head of Zurich Corporate Risk, said Zurich is delighted to partner with Further Group to “significantly enhance” the value-added services available to group risk customers.
“Precision CancerCare™ is a leading edge clinical capability and has huge potential to improve outcomes for individuals with a serious cancer diagnosis.”
Frank Ahedo, chief executive officer at Further, said: “ We have truly found a partner that shares our passion for innovation and our ambition to make a meaningful impact by supporting those facing critical healthcare challenges.”
